Active Ingredient History
Adalimumab, sold under the brand name Humira and others, is a disease-modifying antirheumatic drug and monoclonal antibody used to treat rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, plaque psoriasis, hidradenitis suppurativa, and uveitis. It is administered by subcutaneous injection. It works by inactivating tumor necrosis factor-alpha (TNFα). Wikipedia
Drug Pricing (per unit)
Note: This drug pricing data is preliminary, incomplete, and may contain errors.
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Adalimumab (Phase 4)
Arthritis (Phase 4)
Arthritis, Juvenile (Phase 3)
Asian People (Phase 3)
Asthma (Phase 2)
Autoimmune Diseases (Phase 2)
Axial Spondyloarthritis (Phase 4)
Biological Therapy (Phase 2)
Bursitis (Phase 2/Phase 3)
Cardiovascular Diseases (Phase 4)
Choroidal Neovascularization (Phase 2)
Colitis (Phase 2)
Coronary Artery Disease (Phase 4)
COVID-19 (Phase 3)
Crohn Disease (Phase 4)
Cystitis, Interstitial (Phase 3)
Cytokines (Phase 2)
Dermatitis, Allergic Contact (Phase 2/Phase 3)
Diabetes Mellitus, Type 2 (Phase 4)
Diabetic Retinopathy (Phase 1)
Drug Combinations (Phase 4)
Drug Evaluation (Phase 2/Phase 3)
Drugs, Investigational (Phase 4)
Dupuytren Contracture (Phase 2)
Enterocolitis (Phase 4)
Fibrosis (Phase 3)
Giant Cell Arteritis (Phase 3)
Glomerulosclerosis, Focal Segmental (Phase 2)
Healthy Volunteers (Phase 1)
Hermanski-Pudlak Syndrome (Phase 2)
Hidradenitis Suppurativa (Phase 4)
HIV Infections (Phase 2)
Hypertension (Phase 4)
Immune System Diseases (Phase 4)
Immunity, Innate (Early Phase 1)
Inflammation (Phase 4)
Inflammatory Bowel Diseases (Phase 4)
Intestinal Diseases (Phase 4)
Intestinal Neoplasms (Phase 3)
Joint Diseases (Phase 4)
Lymphocytes (Phase 2)
Macular Degeneration (Phase 2)
Methotrexate (Phase 4)
Mucopolysaccharidosis I (Phase 2/Phase 3)
Mucopolysaccharidosis II (Phase 2/Phase 3)
Mucopolysaccharidosis VI (Phase 2/Phase 3)
Musculoskeletal Diseases (Phase 4)
Myocardium (Phase 4)
Nephrosis, Lipoid (Phase 2)
Netherton Syndrome (Phase 2)
Osteoarthritis (Phase 3)
Osteoarthritis, Knee (Phase 3)
Pain (Phase 3)
Pharmacokinetics (Phase 2/Phase 3)
Pouchitis (Phase 3)
Prostatic Neoplasms (Phase 2)
Psoriasis ()
Pyoderma Gangrenosum (Phase 3)
Rectal Fistula (Phase 4)
Safety (Phase 2/Phase 3)
Sarcoidosis (Phase 2)
Sciatica (Phase 2)
Sleep Apnea, Obstructive (Phase 4)
Spinal Diseases (Phase 3)
Spondylarthropathies (Phase 4)
Substance Withdrawal Syndrome (Phase 3)
Takayasu Arteritis (Phase 4)
Therapeutic Equivalency (Phase 1)
Therapeutics (Phase 4)
Thromboembolism (Phase 4)
Thyroid Carcinoma, Anaplastic (Phase 1)
Tuberculosis, Meningeal (Phase 2)
Ultrasonography (Phase 4)
Uveitis (Phase 4)
Uveitis, Anterior (Phase 4)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue
